Alberto Mantovani

Alberto Mantovani
Born (1948-10-29) October 29, 1948
Milan, Italy
Residence Italy
Citizenship Italian
Fields Immunology
Institutions University of Milan
Humanitas University
University of Brescia
Mario Negri Institute for Pharmacological Research
Alma mater University of Milan
Known for Tumor-associated macrophages
Decoy receptor
CCL2
PTX3
Notable awards Robert Koch Prize, see text for others
Website
Page at Humanitas

Alberto Mantovani Commendatore OMRI (born 29 October 1948) is an Italian physician and immunologist. He is Scientific Director of Istituto Clinico Humanitas (Humanitas Clinical and Research Center), President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan.[1] He is known for his works in the roles of the immune system in the development of cancer. His research on tumor-associated macrophages (TAM, an acronym he coined) established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein - 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.[2]

Biography

Mantovani was born in Milan[1] on 29 October 1948.[3] He studied medicine at the University of Milan and graduated (summa cum laude) in 1973. In 1976 he earned a specialization in oncology at the University of Pavia. Between 1973 and 1976, he worked as a visiting fellow at the Department of Tumor Immunology of the Chester Beatty Research Institute (now the Institute of Cancer Research) in Belmont, Sutton, England, where he continued the studies of Iwan Robert Evans and Peter Alexander. Between 1978 and 1979 he was a visiting fellow at the Laboratory of Immunodiagnosis at the National Institutes of Health in Bethesda, Maryland. In 1979 he was appointed Senior investigator in the Department of Tumor Immunology and Chemotherapy at the Istituto di Ricerche Farmacologiche "Mario Negri" in Milan. He became the Chief of Laboratory of the institute in 1981. In 1987 he worked at the Laboratory of Molecular Immunoregulation of NIH in Frederick, Maryland, as an Eleanor Roosvelt UICC Scholar. In 1994 he was promoted to Full Professor of General Pathology in the School of Medicine at the University of Brescia. He became Head of the Department of Immunology and Cell Biology at Istituto di Ricerche Farmacologiche "Mario Negri" in 1996. Between 2001 and 2014, he also served as Full Professor of General Pathology in the School of Medicine of the State University of Milan. Then he continued as Full Professor of General Pathology at Humanitas University in 2014. In 2005 he became the Scientific Director of Istituto Clinico Humanitas and President of Fondazione Humanitas per la Ricerca (under Humanitas University).[1][2]

Research activities

Following the deepening of the studies by Robert Evans and Peter Alexander on the role of macrophages in tumour formation,[4] Mantovani discovered that macrophages, rather than helping to shrink the tumor, help it to grow and progress.[5] He gave the acronym for such tumor-associated macrophages as TAM. His work in 2013 showed that targeting TAM is useful for cancer treatment.[6] In 1983, his research team has discovered a protein, known as monocyte chemotactic protein - 1 / CCL2, which is part of the large superfamily of chemokines, which belong to the family of cytokines. His works help to establish the concept of "decoy receptors". From the study of the regulation of the cytokines, Mantovani was able to identify the operating principle of the decoy receptor for interleukin - 1. In 1993, his team showed interleukin-1 type II receptor acts as a decoy in the activity of interleukin 1.[7] His team identified the first member of the long pentraxins, named PTX3 in 1997. The discovery was published in a series of papers.[8][9][10] His team demonstrated in 2005 that the chemokine receptor D6 acts as a decoy and scavenger receptor for inflammatory chemokines.[11] In 2015 his research, published in the journal Cell,[12] showed that PTX3 gene is capable of curbing cancer by controlling inflammation.

Works

Scientific Publications

Awards

Honors

Mantovani was appointed "Commander" of the Order of Merit of the Italian Republic in 2005.[17] He was Fellow of the Italian Association Against Leukemias in 1973, and Fellow of the Anna Villa Rusconi Foundation in 1974.[2] He is Vice-President/President Elect of the International Union of Immunological Societies during 2013-2016. He served in the Board of the Global Alliance for Vaccines and Immunization (GAVI) between 2007 and 2010). He was President of the International Cytokine Society during 2009-2010.[18]

References

  1. 1 2 3 "Biography—Alberto Mantovani, MD" (PDF). Cancer and Metastasis Reviews. 29 (2): 239–239. 2010. doi:10.1007/s10555-010-9219-2.
  2. 1 2 3 "Mantovani Alberto, MD". www.humanitas-research.org. Humanitas Clinical and Research Center, Italy. Retrieved 27 July 2016.
  3. ↑ "Curriculum vitae: Mantovani Alberto". www.forumecm.it. Retrieved 29 July 2016.
  4. ↑ Evans, R.; Alexander, P. (1972). "Mechanism of Immunologically Specific Killing of Tumour Cells by Macrophages". Nature. 236 (5343): 168–170. doi:10.1038/236168a0. PMID 4553694.
  5. ↑ Bonavita, E; Galdiero, MR; Jaillon, S; Mantovani, A (2015). "Phagocytes as Corrupted Policemen in Cancer-Related Inflammation.". Advances in Cancer Research. 128: 141–71. doi:10.1016/bs.acr.2015.04.013. PMID 26216632.
  6. ↑ "The Milstein Award: Alberto Montavani". International Cytokine and Interferon Society (ICIS). Retrieved 29 July 2016.
  7. ↑ Colotta, F; Re, F; Muzio, M; Bertini, R; Polentarutti, N; Sironi, M; Giri, J.; Dower, S.; Sims, J.; Mantovani, A (1993). "Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4". Science. 261 (5120): 472–475. doi:10.1126/science.8332913. PMID 8332913.
  8. ↑ Vouret-Craviari, V; Matteucci, C; Peri, G; Poli, G; Introna, M; Mantovani, A (1997). "Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan.". Infection and Immunity. 65 (4): 1345–1350. PMC 175138Freely accessible. PMID 9119472.
  9. ↑ Basile, A; Sica, A; d'Aniello, E; Breviario, F; Garrido, G; Castellano, M; Mantovani, A; Introna, M (1997). "Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation.". The Journal of Biological Chemistry. 272 (13): 8172–8178. doi:10.1074/jbc.272.13.8172. PMID 9079634.
  10. ↑ Bottazzi, B; Vouret-Craviari, V; Bastone, A; De Gioia, L; Matteucci, C; Peri, G; Spreafico, F; Pausa, M; D'Ettorre, C; Gianazza, E; Tagliabue, A; Salmona, M; Tedesco, F; Introna, M; Mantovani, A (1997). "Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component.". The Journal of Biological Chemistry. 272 (52): 32817–32823. doi:10.1074/jbc.272.52.32817. PMID 9407058.
  11. ↑ de la Torre, Yeny Martinez; Locati, Massimo; Buracchi, Chiara; Dupor, Jana; Cook, Donald N.; Bonecchi, Raffaella; Nebuloni, Manuela; Rukavina, Daniel; Vago, Luca; Vecchi, Annunciata; Lira, Sergio A.; Mantovani, Alberto (2005). "Increased inflammation in mice deficient for the chemokine decoy receptor D6". European Journal of Immunology. 35 (5): 1342–1346. doi:10.1002/eji.200526114. PMID 15789340.
  12. ↑ Bonavita, Eduardo; Gentile, Stefania; Rubino, Marcello; Maina, Virginia; Papait, Roberto; Kunderfranco, Paolo; Greco, Carolina; Feruglio, Francesca; Molgora, Martina; Laface, Ilaria; Tartari, Silvia; Doni, Andrea; Pasqualini, Fabio; Barbati, Elisa; Basso, Gianluca; Galdiero, Maria Rosaria; Nebuloni, Manuela; Roncalli, Massimo; Colombo, Piergiuseppe; Laghi, Luigi; Lambris, John D.; Jaillon, Sébastien; Garlanda, Cecilia; Mantovani, Alberto (2015). "PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer". Cell. 160 (4): 700–714. doi:10.1016/j.cell.2015.01.004. PMID 25679762.
  13. ↑ "Alberto Mantovani". Retrieved 15 August 2016.
  14. ↑ http://www1.adnkronos.com/Archivio/AdnSalute/1998/06/22/Farmaceutica/BIOTECNOLOGIE-RICERCA-E-FUTURO-A-BIOTEC-AWARD-1998_163100.php
  15. 1 2 "Biography—Alberto Mantovani, MD". Retrieved 15 August 2016.
  16. ↑ http://opensample.info/featuring-the-guest-editor-alberto-mantovani
  17. ↑ "Commendatore Ordine al Merito della Repubblica Italiana". presidenti.quirinale.it (in Italian). Presidenza della Republica. Retrieved 28 July 2016.
  18. ↑ "Prof Alberto Mantovani". Efranat, Inc. Retrieved 28 July 2016.

External links

This article is issued from Wikipedia - version of the 11/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.